|
|
Reference
|
|
  
|
Bowman, L.J., Brennan, D.C. (2008) The role of tacrolimus in renal transplantation. Expert Opinion on Pharmacotherapy, 9(4): 635-643
|
|
|
Christians, U., Jacobsen, W., Benet, L.Z., Lampen, A. (2002) Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. Clinical Pharmacokinetics, 41(11): 813-851
|
|
|
Finch, A., Pillans, P. (2014) P-glycoprotein and its role in drug-drug interactions. Australian Prescriber, 37(4): 137-139
|
|
1
|
Gabardi, S., Olyaei, J.A. (2010) Solid organ transplantation. u: Chisholm-Burns M.A., Schwinghammer T.L., Wells B.G., Malone P.M., Kolesar J.M., Dipiro J.T. [ur.] Pharmacotherapy Principles and Practice, New York: McGraw Hills Companies, Inc, 939-64
|
|
|
Hane, K., Fujioka, M., Namiki, Y., Kitagawa, T., Kihara, N., Shimatani, K., Yasuda, T. (1992) Physico-chemical properties of (-)-(1R,9S,12S,13R,14S,17R,18E,21 S,23S,24R,27R)-17-allyl-1,14-dihydroxy-12-[(E)- 2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- 1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl- 11,28-dioxa-4-azatricyclo[22.3.1.04. Iyakuhin Kenkyu, 23, 33-43
|
|
1
|
Hosohata, K., Masuda, S., Ogura, Y., Oike, F., Takada, Y., Katsura, T., Uemoto, S., Inui, K. (2008) Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 23(2): 134-138
|
|
|
Isoda, K., Takeuchi, T., Kotani, T., Hirano-Kuwata, S., Shoda, T., Hata, K., Yoshida, S., Makino, S., Hanafusa, T. (2014) The Proton Pump Inhibitor Lansoprazole, but not Rabeprazole, the Increased Blood Concentrations of Calcineurin Inhibitors in Japanese Patients with Connective Tissue Diseases. Internal Medicine, 53(13): 1413-1418
|
|
1
|
Iwasaki, K. (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet, 22(5); 328-35
|
|
|
Jeong, H., Chiou, W.L. (2006) Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica, 36(1): 1-13
|
|
|
Konig, J., Muller, F., Fromm, M.F. (2013) Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects. Pharmacological Reviews, 65(3): 944-966
|
|
|
Kuypers, D.R.J. (2004) The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metabolism and Disposition, 32(12): 1421-1425
|
|
1
|
Leroy, S., Fargue, S., Bensman, A., Deschênes, G., Jacqz-Aigrain, E., Ulinski, T. (2011) Tacrolimus adverse events in transplant recipients with diarrhoea or calcium channel blockers: Systematic review. Medical Case Studies, 2(7): 58-68
|
|
|
Li, J., Wang, X., Chen, S., Liu, L., Fu, Q., Chen, X., Teng, L., Wang, C., Huang, M. (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics Journal, 11(4): 300-306
|
|
|
Li, Y., Yan, L., Shi, Y., Bai, Y., Tang, J., Wang, L. (2015) CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. SpringerPlus, 4(1):
|
|
1
|
Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., Sagae, Y., Habuchi, T., Suzuki, T. (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharmaceutics & Drug Disposition, 28(4): 167-175
|
|
|
Niioka, T., Kagaya, H., Miura, M., Numakura, K., Saito, M., Inoue, T., Habuchi, T., Satoh, S. (2013) Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. European Journal of Clinical Pharmacology, 69(9): 1659-1665
|
|
|
Rančić, N. (2015) Assessment of tacrolimus concentration/dose ratio as a parameter for the therapeutic monitoring in the patients subjected to kidney transplantation. Kragujevac: Faculty of Medical Sciences, Ph.D. Thesis
|
|
5 
|
Rančić, N., Dragojević-Simić, V., Vavić, N., Kovačević, A., Šegrt, Z., Drašković-Pavlović, B., Mikov, M. (2015) Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: The influence of gender and comedication. Vojnosanitetski pregled, vol. 72, br. 9, str. 813-822
|
|
|
Rendić, S., Medić-Šarić, M. (2013) Metabolizam lijekova i odabranih ksenobiotika. Zagreb: Medicinska naklada
|
|
|
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem, 268: 6077-80
|
|
1
|
Shi, W., Tang, H., Zhai, S. (2015) Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. PLOS one, 10(6): e0127995
|
|
|
Shiraga, T., Niwa, T., Teramura, Y., Kagayama, A., Tsutsui, M., Ohno, Y., Iwasaki, K. (1999) Oxidative Metabolism of Tacrolimus and its Metabolite by Human Cytochrome P450 3A Subfamily. Drug Metabolism and Pharmacokinetics, 14(4): 277-285
|
|
|
Staatz, C.E., Tett, S.E. (2004) Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 43(10): 623-653
|
|
3
|
Stefanović, N., Cvetković, T., Veličković-Radovanović, R., Jevtović-Stoimenov, T., Stojanović, D., Živković, N. (2013) Significance of CYP3A5 gene polymorphism in Serbian renal transplant patients. Acta medica Medianae, vol. 52, br. 1, str. 33-38
|
|
37
|
Sweetman, S.C., ur. (2002) Martindale: The complete drug reference. London: Pharmaceutical Press
|
|
1
|
Takahashi, K., Yano, I., Fukuhara, Y., Katsura, T., Takahashi, T., Ito, N., Yamamoto, S., Ogawa, O., Inui, K. (2007) Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient. Drug Metabolism and Pharmacokinetics, 22(6): 441-444
|
|
|
U.S. Food and Drug Administration, Protecting and Promoting Your Health Drug development and drug interactions: Table of substrates, inhibitors and inducers. Last Updated: 10/27/2014. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm (cited 23.10.2015.)
|
|
|
van Maarseveen, E.M., Rogers, C.C., Trofe-Clark, J., van Zuilen, A.D., Mudrikova, T. (2012) Drug-Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review. AIDS Patient Care and STDs, 26(10): 568-581
|
|
5
|
Vavic, N., Rancic, N., Dragojevic-Simic, V., Draskovic-Pavlovic, B., Bokonjic, D., Ignjatovic, L., Mikov, M. (2014) The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. European Journal of Drug Metabolism and Pharmacokinetics, 39(4): 243-253
|
|
4
|
Vavić, N., Rančić, N., Cikota-Aleksić, B., Magić, Z., Cimeša, J., Obrenčević, K., Radojević, M., Mikov, M., Dragojević-Simić, V. (2016) The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation. Vojnosanitetski pregled, vol. 73, br. 7, str. 663-667
|
|
4
|
Velickovic-Radovanovic, R., Mikov, M., Catic-Djordjevic, A., Stefanovic, N., Mitic, B., Paunovic, G., Cvetkovic, T. (2015) Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. European Journal of Drug Metabolism and Pharmacokinetics, 40(1): 95-102
|
|
|
Wallemacq, P.E., Verbeeck, R.K. (2001) Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients. Clinical Pharmacokinetics, 40(4): 283-295
|
|
1
|
Zhao, W., Baudouin, V., Fakhoury, M., Storme, T., Deschênes, G., Jacqz-Aigrain, E. (2012) Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child. Transplantation, 93(7): e29-e30
|
|
|
|
|